Bisphosphonates for post-menopausal osteoporosis: Are they all the same?

QJM: An International Journal of Medicine

Volumn 104, Issue 4, 2011, Pages 281-300

  Rizzoli, R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; BONE DENSITOMETRY; BONE PAIN; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FEMUR SUBTROCHANTERIC FRACTURE; FLATULENCE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MORTALITY; NAUSEA; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; STOMACH ULCER; VERTEBRA FRACTURE; VOMITING;

EID: 79953835860     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq259     Document Type: Review

References (94)

1. International Osteoporosis Foundation 2009. About Osteoporosis: Prevention. [http://www.iofbonehealth.org/patients-public/about-osteoporosis/prevent ion.html] Accessed 27 October 2010.
2. European Medicines Agency 2006. Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. CPMP/EWP/552/95 Rev. 2. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideli ne/2009/09/WC500003405.pdf] Accessed 27 October 2010.
3. Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2:53-63.
4. Naylor CD. What is appropriate care? N Engl J Med 1998; 338:1918-20.
5. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148:197-213.
6. World Health Organization 2003. Prevention and Management of Osteoporosis. WHO Technical Report Series 921. [http://whqlibdoc.who.int/trs/who_trs_921.pdf] Accessed 27 October 2010.
7. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399-428.
8. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38:617-27.
9. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733-59.
10. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-42.
11. Mitchell DY, Barr WH, Eusebio RA, Stevens KA, Duke FP, Russell DA, et al. Risedronate pharmacokinetics and intraand inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 2001; 18:166-70.
12. Roche Registration Limited. Bonviva Summary of Product Characteristics. 2010. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Inf ormation/human/000501/WC500052652.pdf] Accessed 12 January 2011.
13. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12:1700-7.
14. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42:1228-36.
15. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58:288-98.
16. Tanko LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003; 32:421-6.
17. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
18. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-22.
19. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-9.
20. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077-82.
21. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-52.
22. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11:83-91.
23. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized doubleblind study. J Bone Miner Res 2005; 20:141-51.
24. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007; 40:1238-43.
25. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009; 44:758-65.
26. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18:25-34.
27. Ringe JD, Doherty JG. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 2010; 30:863-9.
28. Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT)-needs treatment with care. Basic Clin Pharmacol Toxicol 2006; 99:12-6.
29. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927-38.
30. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-40.
31. Genant HK, Wu CY, van KC, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8:1137-48.
32. Smith-Bindman R, Cummings SR, Steiger P, Genant HK. A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res 1991; 6:25-34.
33. Merck Sharp & Dohme Limited. Fosamax Summary of Product Characteristics. 2010. [http://www.medicines.org.uk/emc/medicine/1175/SPC/Fosamax/] Accessed 12 January 2011.
34. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20:1315-22.
35. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65:654-61.
36. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-43.
37. Novartis Pharma Stein AG. Reclast (Zoledronic Acid) Injection Prescribing Information. 2010. [http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf] Accessed 12 January 2011.
38. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogenbisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001; 59:193-202.
39. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003; 23:649-54.
40. Thompson K, Rogers MJ. Statins prevent bisphosphonateinduced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19:278-88.
41. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-809.
42. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010; 95:4380-7.
43. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007; 356:1895-6.
44. Camm JA. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 2010; 32:426-36.
45. Chapurlat RD. Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. Ther Clin Risk Manag 2009; 5:169-75.
46. Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. Br Med J 2008; 336:813-6.
47. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009; 84:632-7.
48. US Food and Drug Administration 2008. Safety alerts for human medical products. Bisphosphonates marketed as alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/calcium), tiludronate (Skelid), zoledronic acid (Reclast, Zometa). [http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHum an MedicalProducts/ucm079352.htm] Accessed 27 October 2010.
49. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 2006; 355:2278-81.
50. Khan AA, Sandor GKB, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36:478-90.
51. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42:841-7.
52. Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139:32-40.
53. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009; 85:37-44.
54. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89:349-53.
55. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009; 32:775-85.
56. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39:224-31.
57. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor- Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20:1353-62.
58. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346-50.
59. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-301.
60. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362:1761-71.
61. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 2010; 47:169-80.
62. European Medicines Agency 2009. Assessment report for Fosavance. EMEA/CHMP/188952/2009. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_ Report_-_Variatio/human/000619/WC500024252.pdf] Accessed 27 October 2010.
63. Merck Sharp and Dohme Limited. Fosavance Summary of Product Characteristics. 2010. [http://www.medicines.org.uk/emc/medicine/16569/SPC/] Accessed 12 January 2011.
64. Rizzoli R, Åkesson K, Bouxsein M, Kanis J, Napoli N, Papapoulos S, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2010.
65. von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 2008; 16:1105-15.
66. Procter and Gamble Pharmaceuticals. Actonel Summary of Product Characteristics. 2010. [http://www.medicines.org.uk/EMC/medicine/11591/SPC/ Actonel+Once+a+Week+35mg+film+coated+tablets./] Accessed 12 January 2011.
67. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008; 74:641-8.
68. US Food and Drug Administration 2009. Drug Safety Newsletter. Vol. 2, Number 2. [http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/UCM1 68579.pdf] Accessed 27 October 2010.
69. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005; 10(Suppl. 1):3-7.
70. Luhe A, Kunkele KP, Haiker M, Schad K, Zihlmann C, Bauss F, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008; 22:899-909.
71. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:89-90.
72. Hofbauer LC, Miehlke S. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:1790-2.
73. Robins HI, Holen KD. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:1790-2.
74. Siris ES, Oster MW, Bilezikian JP. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:1791-2.
75. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:1789.
76. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:1789-90.
77. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010; 95:1174-81.
78. Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskel Dis 2010; 2:3-16.
79. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. NOF 2002; 2:5-7.
80. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009; 30:213-21.
81. National Institute for Health and Clinical Excellence 2010 Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE Technology Appraisal Guidance 160 (Amended). [http://www.nice.org.uk/nicemedia/live/11746/47176/47176.pdf] Accessed 27 October 2010.
82. National Osteoporosis Foundation of South Africa. Use of generic alendronate in the treatment of osteoporosis. S Afr Med J 2006; 96:696-7.
83. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013-22.
84. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165:2414-9.
85. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003-8.
86. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38:922-8.
87. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006; 22:1757-64.
88. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007; 41:122-8.
89. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 2001; 94:575-97.
90. Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 2009; 20:1583-94.
91. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 2003; 68:341-4.
92. Wright S, Yelland M, Heathcote K, Ng SK, Wright G. Fear of needles-nature and prevalence in general practice. Aust Fam Physician 2009; 38:172-6.
93. Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007; 13(Suppl 11):S290-308.
94. Catterall JB, Cawston TE. Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther 2003; 5:12-24.